Yahoo Web Search

Search results

  1. People also ask

  2. 1 day ago · Avalo Therapeutics (NASDAQ: AVTX) just reported results for the first quarter of 2024. Avalo Therapeutics reported earnings per share of -$6.11. This was below the analyst estimate for EPS of -$1. ...

  3. 5 days ago · Avalo Therapeutics - AVTX - Stock Price Today - Zacks. Avalo Therapeutics (AVTX) (Delayed Data from NSDQ) $11.73 USD. -1.52 (-11.47%) Updated May 8, 2024 04:00 PM ET. After-Market: $11.62...

  4. 6 days ago · Avalo Therapeutics, Inc. (AVTX) Stock Price, Quote & News - Stock Analysis. NASDAQ: AVTX · IEX Real-Time Price · USD. 11.73. -1.52 (-11.47%) At close: May 8, 2024, 4:00 PM. 11.79. +0.06 (0.51%) After-hours: May 8, 2024, 7:41 PM EDT. Overview. Financials. Statistics. Forecast. Profile. Chart. 1D. 5D. 1M. YTD. 1Y. 5Y. Max. -11.47% ( 1D) News. All.

    • AVTX Stock1
    • AVTX Stock2
    • AVTX Stock3
    • AVTX Stock4
  5. 1 day ago · Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and ...

  6. 17 hours ago · Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027. WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. “Over the past month we have made considerable ...

  7. 16 hours ago · May 13, 2024 8:05 AM ET Avalo Therapeutics, Inc. (AVTX) Stock By: Deepa Sarvaiya, SA News Editor. Avalo Therapeutics press release ( NASDAQ: AVTX ): Q1 net loss of $121.3 million. Cash on hand of ...

  8. 4 days ago · RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier. 23-05-10. MT. Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50.

  1. People also search for